Developer docs
API playgroundTry for free, no card

Search company profiles

Foresight Diagnostics

Full company profile

uuid0000u63

Namestring
Foresight Diagnostics
Legal namestring
Foresight Diagnostics
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Foresight Diagnostics is a precision genomics company founded in 2020 and headquartered in Boulder, Colorado, that develops and commercializes ultra-sensitive circulating tumor DNA (ctDNA) liquid biopsy tests for cancer minimal residual disease (MRD) detection and monitoring. The company's core technology, PhasED-Seq (Phased Variant Sequencing), was developed by four Stanford University physician-scientists and detects ctDNA at limits below 0.1 parts per million by tracking two or more single nucleotide variants on the same DNA molecule, claimed to be up to 100x more sensitive than first-generation liquid biopsy methods. The commercial product, Foresight CLARITY, is offered as a laboratory-developed test (LDT) through Foresight's automated, CLIA-certified, and CAP-accredited central laboratory in Boulder, with applications in B-cell lymphoma (DLBCL, follicular lymphoma, classic Hodgkin lymphoma) and exploratory solid tumor indications (NSCLC, breast cancer).

Foresight operates a B2B, sales-led go-to-market model with three revenue streams: diagnostic testing services processed through its CLIA lab, biopharma services including companion diagnostic development and clinical trial execution support (using MRD as enrollment biomarker or surrogate endpoint for event-free survival), and academic research services. The company serves biopharma companies conducting oncology drug development, academic medical centers, and clinical trial sponsors, with named partners including Allogene Therapeutics (ALPHA3 pivotal trial), Bristol Myers Squibb (TRANSFORM/liso-cel study), and Memorial Sloan Kettering Cancer Center. As of acquisition, the company maintained 30+ biopharma and academic research partnerships and had produced 40+ peer-reviewed publications demonstrating clinical validity, including inclusion in NCCN Clinical Practice Guidelines for DLBCL. Pricing is not publicly disclosed and is handled through direct service agreements.

In December 2025, Foresight was acquired by Natera, Inc. in an all-stock transaction valued at $275 million upfront plus up to $175 million in milestone-based earnouts tied to revenue and reimbursement milestones. Following the acquisition, Foresight operates as a wholly-owned subsidiary of Natera, with its PhasED-Seq technology integrated into Natera's Signatera MRD platform and an enhanced test made available for research use, with clinical launch anticipated in 2026.

Short descriptiontext

Foresight Diagnostics develops ultra-sensitive liquid biopsy tests for cancer minimal residual disease (MRD) detection using its proprietary PhasED-Seq technology. The Boulder, Colorado-based company serves biopharma firms and academic researchers through its CLIA-certified lab, and was acquired by Natera in December 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, minimal residual disease testing, ctDNA detection technology, companion diagnostic development, precision genomics oncology
Industry4 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics / Liquid Biopsy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Testing Services
TypeOne Time License
Description

Foresight Diagnostics provides MRD testing services through its CLIA-certified central laboratory in Boulder, Colorado, offering its Foresight CLARITY liquid biopsy platform for B-cell lymphoma and solid tumor applications.

foresight-dx.com
2Biopharma Services (CDx Development & Clinical Trial Execution)
TypeProfessional Services
Description

The company offers companion diagnostic development, clinical trial execution support, and translational research services to biopharma partners, enabling MRD as an endpoint or patient enrollment biomarker in clinical trials.

foresight-dx.com
3Academic Research Services
TypeProfessional Services
Description

Services for academic researchers including access to Foresight CLARITY MRD technology for exploratory research and study design support in oncology.

foresight-dx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1PhasED-Seq
Description

Proprietary ctDNA technology platform that tracks phased variants for enhanced detection limits below one part per million, up to 100 times more sensitive than first-generation liquid biopsy methods.

foresight-dx.com
+1 more record
Core offering1 text field

Foresight Diagnostics develops and delivers the Foresight CLARITY MRD testing platform, an ultra-sensitive liquid biopsy assay powered by proprietary PhasED-Seq technology that detects circulating tumor DNA at sub-part-per-million levels for minimal residual disease monitoring in cancer patients. The company provides centralized CLIA-certified laboratory testing services for B-cell lymphoma and solid tumor applications, plus companion diagnostic development and clinical trial execution services for biopharma and academic research partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Detection limit below 0.1 parts per million — up to 100x more sensitive than first-generation liquid biopsy methods
+4 more records
Product and service4 records
1Foresight CLARITY MRD Platform — B-cell Lymphoma
CategoryLiquid Biopsy / Cancer Diagnostics
Description

Fixed, off-the-shelf laboratory-developed test for ultra-sensitive minimal residual disease detection and recurrence monitoring in B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL/LBCL), follicular lymphoma, and classic Hodgkin lymphoma. The assay detects ctDNA at sub-part-per-million levels and can identify relapse up to 200 days earlier than standard PET/CT imaging. It is intended for use in clinical research, drug development, and post-treatment disease monitoring.

2Foresight CLARITY MRD Platform — Solid Tumors
CategoryLiquid Biopsy / Cancer Diagnostics
Description

Personalized, ultra-sensitive minimal residual disease assay for exploratory research in solid tumor cancers, including non-small cell lung cancer (NSCLC) and breast cancer. The assay uses patient- and tumor-specific phased variants and has demonstrated improved clinical sensitivity at the post-surgical landmark versus first-generation SNV methods, enabling identification of high-risk post-surgical patients who may benefit from adjuvant therapy.

3Biopharma Services — Companion Diagnostic Development & Clinical Trial Execution
CategoryBiopharma Services / Clinical Research
Description

Service offering for biopharmaceutical companies that includes companion diagnostic (CDx) development, clinical trial execution support using MRD as an enrollment biomarker and as a clinical trial endpoint, and translational research services. Foresight serves as a research, regulatory, and commercialization partner for biopharma customers.

4Academic Research Services
CategoryAcademic Research Services
Description

Service offering for academic medical centers and researchers providing access to the Foresight CLARITY MRD platform for exploratory cancer research, ctDNA monitoring studies, and collaborative research programs, including bioinformatics and study design support.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Foresight Diagnostics partnered with Allogene Therapeutics to develop a MRD-based in vitro diagnostic (IVD) for use in the ALPHA3 Phase 2 pivotal trial — the first pivotal trial for frontline consolidation in newly diagnosed large B-cell lymphoma patients. Foresight serves as the research, regulatory, and commercialization partner for the companion diagnostic. The company initiated its pivotal Phase 2 ALPHA3 clinical trial in 2024 in partnership with Allogene.

2Bristol Myers Squibb
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Bristol Myers Squibb collaborated with Foresight Diagnostics using ctDNA analysis via Foresight CLARITY to predict early response to liso-cel (lisocabtagene maraleucel) in a retrospective analysis of their TRANSFORM Phase 3 study for large B-cell lymphoma. Foresight's technology was used to demonstrate that undetectable ctDNA after liso-cel treatment strongly correlated with longer event-free survival.

foresight-dx.com
330+ Academic and Biopharma Research Partners
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Foresight maintains partnerships with more than 30 biopharma and academic researchers. These collaborations span across lymphoma and solid tumor research programs, with partners using Foresight CLARITY for MRD as an enrollment biomarker and as a clinical trial endpoint. Partnerships include translational research interrogating the relationship between MRD and therapeutic response.

foresight-dx.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

MSKCC researchers collaborated with Foresight Diagnostics to present data at ASCO 2024 on ultrasensitive ctDNA MRD monitoring in early-stage NSCLC using PhasED-Seq, demonstrating improved clinical sensitivity at post-surgical landmark vs. first-generation SNV methods.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Tempus AI
TypeBroad incumbent
Description

Tempus offers xT, xR, and other oncology testing products spanning tumor profiling, MRD, and multi-modal data. While Tempus is broader than Foresight, its liquid biopsy and biopharma services business directly competes in the same oncology diagnostics and trial-services market.

TypeDirect peer
Description

NeoGenomics provides oncology-focused laboratory services including liquid biopsy and MRD assays through its RaDaR and other oncology tests. It competes with Foresight in providing biopharma trial-support services and clinical oncology diagnostics.

TypeDirect peer
Description

Personalis offers NeXT Personal, a tumor-informed liquid biopsy MRD assay using whole-genome sequencing. It is a direct MRD peer with overlapping biopharma services offerings and similar sensitivity-focused positioning versus first-generation ctDNA assays.

TypeDirect peer
Description

Caris offers MI Profile and MI Cancer Seek for comprehensive molecular profiling, plus biopharma services. It competes with Foresight in oncology liquid biopsy testing and biopharma companion diagnostic partnerships.

TypeDirect peer
Description

Adaptive Biotechnologies offers clonoSEQ, the FDA-cleared MRD test for lymphoid malignancies. clonoSEQ uses immune receptor sequencing rather than ctDNA but is the dominant blood-based MRD assay in lymphoma, directly competing with Foresight CLARITY in DLBCL.

TypeDirect peer
Description

Foundation Medicine (a Roche subsidiary) provides FoundationOne Liquid CDx, a comprehensive liquid biopsy assay for tumor profiling and emerging MRD applications. It competes with Foresight CLARITY for biopharma CDx development and oncology testing share.

7GRAIL
TypeDirect peer
Description

GRAIL develops Galleri, a multi-cancer early detection test based on methylation-based ctDNA analysis. While Galleri targets screening rather than MRD, GRAIL's deep ctDNA technology capabilities and biopharma partnerships make it a relevant oncology liquid biopsy peer.

TypeBroad incumbent
Description

Exact Sciences offers Oncotype DX, Cologuard, and the Therascreen/Precision Oncology portfolio, including MRD initiatives. As a major publicly traded oncology diagnostics incumbent, it is comparable to Foresight/Natera in the broader oncology testing market.

TypeDirect peer
Description

Guardant Health offers Guardant360 for tumor profiling and Guardant Reveal for MRD detection, both liquid biopsy products. It competes directly with Foresight/Natera in oncology ctDNA-based testing across biopharma services and clinical diagnostics.

TypeDirect peer
Description

Natera operates Signatera, the leading tumor-informed MRD test, and acquired Foresight Diagnostics in December 2025 to integrate PhasED-Seq. Signatera and Foresight CLARITY address the same MRD market across biopharma, academic, and clinical customers with overlapping workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Foresight Diagnostics

Cancer Diagnostics / Liquid Biopsyforesight-dx.com

Foresight Diagnostics develops ultra-sensitive liquid biopsy tests for cancer minimal residual disease (MRD) detection using its proprietary PhasED-Seq technology. The Boulder, Colorado-based company serves biopharma firms and academic researchers through its CLIA-certified lab, and was acquired by Natera in December 2025.

What Foresight Diagnostics does

Foresight Diagnostics is a precision genomics company founded in 2020 and headquartered in Boulder, Colorado, that develops and commercializes ultra-sensitive circulating tumor DNA (ctDNA) liquid biopsy tests for cancer minimal residual disease (MRD) detection and monitoring. The company's core technology, PhasED-Seq (Phased Variant Sequencing), was developed by four Stanford University physician-scientists and detects ctDNA at limits below 0.1 parts per million by tracking two or more single nucleotide variants on the same DNA molecule, claimed to be up to 100x more sensitive than first-generation liquid biopsy methods. The commercial product, Foresight CLARITY, is offered as a laboratory-developed test (LDT) through Foresight's automated, CLIA-certified, and CAP-accredited central laboratory in Boulder, with applications in B-cell lymphoma (DLBCL, follicular lymphoma, classic Hodgkin lymphoma) and exploratory solid tumor indications (NSCLC, breast cancer).

Foresight operates a B2B, sales-led go-to-market model with three revenue streams: diagnostic testing services processed through its CLIA lab, biopharma services including companion diagnostic development and clinical trial execution support (using MRD as enrollment biomarker or surrogate endpoint for event-free survival), and academic research services. The company serves biopharma companies conducting oncology drug development, academic medical centers, and clinical trial sponsors, with named partners including Allogene Therapeutics (ALPHA3 pivotal trial), Bristol Myers Squibb (TRANSFORM/liso-cel study), and Memorial Sloan Kettering Cancer Center. As of acquisition, the company maintained 30+ biopharma and academic research partnerships and had produced 40+ peer-reviewed publications demonstrating clinical validity, including inclusion in NCCN Clinical Practice Guidelines for DLBCL. Pricing is not publicly disclosed and is handled through direct service agreements.

In December 2025, Foresight was acquired by Natera, Inc. in an all-stock transaction valued at $275 million upfront plus up to $175 million in milestone-based earnouts tied to revenue and reimbursement milestones. Following the acquisition, Foresight operates as a wholly-owned subsidiary of Natera, with its PhasED-Seq technology integrated into Natera's Signatera MRD platform and an enhanced test made available for research use, with clinical launch anticipated in 2026.

Foresight Diagnostics firmographics

Firmographics
Name
Foresight Diagnostics
Legal name
Foresight Diagnostics
Website
https://foresight-dx.com
Company type
Private
Founded year
2020
Operating status
Acquired
Headcount range
101–250 employees
Short description
Foresight Diagnostics develops ultra-sensitive liquid biopsy tests for cancer minimal residual disease (MRD) detection using its proprietary PhasED-Seq technology. The Boulder, Colorado-based company serves biopharma firms and academic researchers through its CLIA-certified lab, and was acquired by Natera in December 2025.
Ownership category
akta.pro rank

Foresight Diagnostics industry classification

Industry
Product category
Cancer Diagnostics / Liquid Biopsy
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Liquid biopsy diagnostics
  • Minimal residual disease testing
  • CtDNA detection technology
  • Companion diagnostic development
  • Precision genomics oncology

Where Foresight Diagnostics is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Foresight Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Diagnostic Testing Services: Foresight Diagnostics provides MRD testing services through its CLIA-certified central laboratory in Boulder, Colorado, offering its Foresight CLARITY liquid biopsy platform for B-cell lymphoma and solid tumor applications.
  2. Biopharma Services (CDx Development & Clinical Trial Execution): The company offers companion diagnostic development, clinical trial execution support, and translational research services to biopharma partners, enabling MRD as an endpoint or patient enrollment biomarker in clinical trials.
  3. Academic Research Services: Services for academic researchers including access to Foresight CLARITY MRD technology for exploratory research and study design support in oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Foresight Diagnostics product offering

Product offering

Core offering

Foresight Diagnostics develops and delivers the Foresight CLARITY MRD testing platform, an ultra-sensitive liquid biopsy assay powered by proprietary PhasED-Seq technology that detects circulating tumor DNA at sub-part-per-million levels for minimal residual disease monitoring in cancer patients. The company provides centralized CLIA-certified laboratory testing services for B-cell lymphoma and solid tumor applications, plus companion diagnostic development and clinical trial execution services for biopharma and academic research partners.

Differentiator

Problem solved

Functional benefit

Brands

  • PhasED-Seq: Proprietary ctDNA technology platform that tracks phased variants for enhanced detection limits below one part per million, up to 100 times more sensitive than first-generation liquid biopsy methods.
  • Foresight CLARITY

Products and services

  • Foresight CLARITY MRD Platform — B-cell Lymphoma Fixed, off-the-shelf laboratory-developed test for ultra-sensitive minimal residual disease detection and recurrence monitoring in B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL/LBCL), follicular lymphoma, and classic Hodgkin lymphoma. The assay detects ctDNA at sub-part-per-million levels and can identify relapse up to 200 days earlier than standard PET/CT imaging. It is intended for use in clinical research, drug development, and post-treatment disease monitoring.
  • Foresight CLARITY MRD Platform — Solid Tumors Personalized, ultra-sensitive minimal residual disease assay for exploratory research in solid tumor cancers, including non-small cell lung cancer (NSCLC) and breast cancer. The assay uses patient- and tumor-specific phased variants and has demonstrated improved clinical sensitivity at the post-surgical landmark versus first-generation SNV methods, enabling identification of high-risk post-surgical patients who may benefit from adjuvant therapy.
  • Biopharma Services — Companion Diagnostic Development & Clinical Trial Execution Service offering for biopharmaceutical companies that includes companion diagnostic (CDx) development, clinical trial execution support using MRD as an enrollment biomarker and as a clinical trial endpoint, and translational research services. Foresight serves as a research, regulatory, and commercialization partner for biopharma customers.
  • Academic Research Services Service offering for academic medical centers and researchers providing access to the Foresight CLARITY MRD platform for exploratory cancer research, ctDNA monitoring studies, and collaborative research programs, including bioinformatics and study design support.

Quantifiable outcome

  • Detection limit below 0.1 parts per million — up to 100x more sensitive than first-generation liquid biopsy methods
  • +4 more outcomes

Companies that use Foresight Diagnostics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Foresight Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Foresight Diagnostics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Allogene TherapeuticscoreStrategic or Co-development PartnerForesight Diagnostics partnered with Allogene Therapeutics to develop a MRD-based in vitro diagnostic (IVD) for use in the ALPHA3 Phase 2 pivotal trial — the first pivotal trial for frontline consolidation in newly diagnosed large B-cell lymphoma patients. Foresight serves as the research, regulatory, and commercialization partner for the companion diagnostic. The company initiated its pivotal Phase 2 ALPHA3 clinical trial in 2024 in partnership with Allogene.
  • Bristol Myers SquibbsupportingStrategic or Co-development PartnerBristol Myers Squibb collaborated with Foresight Diagnostics using ctDNA analysis via Foresight CLARITY to predict early response to liso-cel (lisocabtagene maraleucel) in a retrospective analysis of their TRANSFORM Phase 3 study for large B-cell lymphoma. Foresight's technology was used to demonstrate that undetectable ctDNA after liso-cel treatment strongly correlated with longer event-free survival.
  • 30+ Academic and Biopharma Research PartnerssupportingStrategic or Co-development PartnerForesight maintains partnerships with more than 30 biopharma and academic researchers. These collaborations span across lymphoma and solid tumor research programs, with partners using Foresight CLARITY for MRD as an enrollment biomarker and as a clinical trial endpoint. Partnerships include translational research interrogating the relationship between MRD and therapeutic response.
  • Memorial Sloan Kettering Cancer Center (MSKCC)supportingStrategic or Co-development PartnerMSKCC researchers collaborated with Foresight Diagnostics to present data at ASCO 2024 on ultrasensitive ctDNA MRD monitoring in early-stage NSCLC using PhasED-Seq, demonstrating improved clinical sensitivity at post-surgical landmark vs. first-generation SNV methods.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Foresight Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Tempus AI: Tempus offers xT, xR, and other oncology testing products spanning tumor profiling, MRD, and multi-modal data. While Tempus is broader than Foresight, its liquid biopsy and biopharma services business directly competes in the same oncology diagnostics and trial-services market.
  • Exact Sciences: Exact Sciences offers Oncotype DX, Cologuard, and the Therascreen/Precision Oncology portfolio, including MRD initiatives. As a major publicly traded oncology diagnostics incumbent, it is comparable to Foresight/Natera in the broader oncology testing market.

Direct peers

  • NeoGenomics: NeoGenomics provides oncology-focused laboratory services including liquid biopsy and MRD assays through its RaDaR and other oncology tests. It competes with Foresight in providing biopharma trial-support services and clinical oncology diagnostics.
  • Personalis: Personalis offers NeXT Personal, a tumor-informed liquid biopsy MRD assay using whole-genome sequencing. It is a direct MRD peer with overlapping biopharma services offerings and similar sensitivity-focused positioning versus first-generation ctDNA assays.
  • Caris Life Sciences: Caris offers MI Profile and MI Cancer Seek for comprehensive molecular profiling, plus biopharma services. It competes with Foresight in oncology liquid biopsy testing and biopharma companion diagnostic partnerships.
  • Adaptive Biotechnologies: Adaptive Biotechnologies offers clonoSEQ, the FDA-cleared MRD test for lymphoid malignancies. clonoSEQ uses immune receptor sequencing rather than ctDNA but is the dominant blood-based MRD assay in lymphoma, directly competing with Foresight CLARITY in DLBCL.
  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides FoundationOne Liquid CDx, a comprehensive liquid biopsy assay for tumor profiling and emerging MRD applications. It competes with Foresight CLARITY for biopharma CDx development and oncology testing share.
  • GRAIL: GRAIL develops Galleri, a multi-cancer early detection test based on methylation-based ctDNA analysis. While Galleri targets screening rather than MRD, GRAIL's deep ctDNA technology capabilities and biopharma partnerships make it a relevant oncology liquid biopsy peer.
  • Guardant Health: Guardant Health offers Guardant360 for tumor profiling and Guardant Reveal for MRD detection, both liquid biopsy products. It competes directly with Foresight/Natera in oncology ctDNA-based testing across biopharma services and clinical diagnostics.
  • Natera: Natera operates Signatera, the leading tumor-informed MRD test, and acquired Foresight Diagnostics in December 2025 to integrate PhasED-Seq. Signatera and Foresight CLARITY address the same MRD market across biopharma, academic, and clinical customers with overlapping workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Foresight Diagnostics social profiles

Digital presence

Foresight Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Foresight Diagnostics leadership team

Management profile

Number of profiles

Profiles20 records

Foresight Diagnostics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Foresight Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foresight Diagnostics

What does Foresight Diagnostics do?

Foresight Diagnostics develops and delivers the Foresight CLARITY MRD testing platform, an ultra-sensitive liquid biopsy assay powered by proprietary PhasED-Seq technology that detects circulating tumor DNA at sub-part-per-million levels for minimal residual disease monitoring in cancer patients. The company provides centralized CLIA-certified laboratory testing services for B-cell lymphoma and solid tumor applications, plus companion diagnostic development and clinical trial execution services for biopharma and academic research partners.

Is Foresight Diagnostics a public or private company?

Foresight Diagnostics is a private company. It is classified as corporate owned and is currently acquired.

When was Foresight Diagnostics founded?

Foresight Diagnostics was founded in 2020. It employs 101 to 250 people.

Where is Foresight Diagnostics based?

Foresight Diagnostics is headquartered in Boulder, United States, in the North America region.

How does Foresight Diagnostics make money?

Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are biopharma Services (CDx Development & Clinical Trial Execution) and academic Research Services.

Who are Foresight Diagnostics's main competitors?

Broad incumbents on record are Tempus AI and Exact Sciences. Direct peers are NeoGenomics, Personalis, Caris Life Sciences, Adaptive Biotechnologies, Foundation Medicine, GRAIL, Guardant Health and Natera.

Does Foresight Diagnostics have an API?

No public API is recorded for Foresight Diagnostics.

What industry is Foresight Diagnostics in?

Foresight Diagnostics's product category is Cancer Diagnostics / Liquid Biopsy. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCancer Diagnostics Market worth $44.92 billion by 2031 - Exclusive Report by MarketsandMarkets™The cancer diagnostics market is projected to grow from $29.86 billion in 2026 to $44.92 billion by 2031, a 7.0% CAGR. Asia Pacific is expected to lead growth, and IVD testing instruments and clinical laboratories are the leading product and end-user segments.PR NewswireCancer Tumor Profiling Market worth $19.87 billion by 2031 - Exclusive Report by MarketsandMarkets™The cancer tumor profiling market is projected to grow from $12.02 billion in 2026 to $19.87 billion by 2031, a CAGR of 10.6%. North America held the largest regional share in 2025, while Asia Pacific is expected to see the fastest growth at 12.8%. M&A activity is focused on MRD, AI pathology, and liquid biopsy platforms.Market ScoopCancer-focused Genetic Testing Service MarketThe global cancer-focused genetic testing service market is projected to grow from US$ 8.5 billion in 2024 to US$ 19.6 billion by 2034, at a CAGR of 8.7%, driven by rising cancer incidence and increasing demand for precision oncology therapies. In December 2025, Natera announced the acquisition of Foresight Diagnostics for up to US$ 450 million to enhance its minimal residual disease testing platform, while Myriad Genetics and QIAGEN made strategic moves in early 2024 to expand their liquid biopsy and next-generation sequencing capabilities. North America dominated the market with a 43.1% share in 2024, though Asia Pacific is expected to post the highest growth rate during the forecast period.Pulse 2.0Natera Completes Acquisition Of Foresight Diagnostics For Up To $450 MillionNatera completed its acquisition of Foresight Diagnostics, paying $275 million upfront in stock and $175 million tied to revenue and reimbursement milestones. Foresight's phased variant technology, validated across 40+ publications, will be integrated into Natera's Signatera platform, with a clinical launch expected in 2026.MedTech DiveNatera acquires Foresight Diagnostics for up to $450MNatera completed its acquisition of Foresight Diagnostics for $275 million upfront plus up to $175 million in milestone payments, expanding its position in solid tumor molecular residual disease detection, particularly in lymphoma. Foresight's PhasED-Seq technology, which claims to be up to 100 times more sensitive than first-generation liquid biopsy methods, will be integrated into Natera's Signatera platform. The enhanced Signatera test is immediately available for research use with biopharma and academic partners and is expected to launch for clinical use in 2026.Clinical Lab ProductsNatera Acquires Foresight Diagnostics in $450 Million DealNatera Inc completed its acquisition of Foresight Diagnostics in an all-stock transaction valued at up to $450 million, with $275 million paid upfront and up to $175 million in earnouts tied to revenue and reimbursement milestones. The deal adds Foresight's PhasED-Seq technology, which has demonstrated detection capabilities below 0.1 parts per million, and accelerates Natera's expansion into lymphoma testing alongside its existing solid tumor MRD capabilities. Foresight, founded by Stanford University researchers, has produced over 40 scientific publications and maintains partnerships with more than 30 biopharma and academic researchers.Investing.comNatera acquires Foresight Diagnostics to expand cancer detection capabilities By Investing.comNatera, Inc. has completed the acquisition of Foresight Diagnostics in an all-stock transaction valued at $275 million upfront, with additional potential earnouts of up to $175 million tied to revenue and reimbursement milestones. The deal combines Natera's commercial MRD testing infrastructure with Foresight's phased variant technology, which can detect cancer DNA at concentrations as low as 0.1 parts per million, and is expected to strengthen Natera's position in solid tumor MRD testing and accelerate expansion into lymphoma. Foresight's enhanced Signatera platform is immediately available for research use with clinical launch anticipated in 2026.BioSpaceNatera Acquires Foresight DiagnosticsNatera, Inc. has completed its acquisition of Foresight Diagnostics in an all-stock transaction valued at $275 million upfront plus up to $175 million in earnouts tied to revenue and reimbursement milestones. The acquisition integrates Foresight's ultrasensitive PhasED-Seq technology, which achieves detection limits below 0.1 parts per million, into Natera's existing Signatera MRD platform and adds leadership in lymphoma diagnostics, with ctDNA MRD recently incorporated into NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma. The combined entity expects to launch the enhanced Signatera platform for clinical use in 2026 and will present 15 abstracts at the upcoming ASH Annual Meeting.Investing.comNatera acquires Foresight Diagnostics to expand cancer detection capabilities By Investing.comNatera has completed the $275 million acquisition of Foresight Diagnostics, adding its phased variant technology to expand capabilities in solid tumor and lymphoma molecular residual disease testing. The deal is expected to accelerate Natera's market position in precision oncology, with an enhanced platform incorporating Foresight’s technology anticipated for clinical launch in 2026.Stock TitanNatera acquires Foresight Diagnostics in $275M stock dealNatera, Inc. has completed its acquisition of Foresight Diagnostics in an all-stock transaction valued at $275 million upfront, with up to $175 million in additional earnouts tied to revenue and reimbursement milestones. The deal integrates Foresight's ultrasensitive PhasED-Seq technology and lymphoma research capabilities into Natera's Signatera MRD testing platform, with enhanced clinical availability expected in 2026. The acquisition reinforces Natera's position in precision oncology by combining its commercial infrastructure with Foresight's patented phased variant detection technology, which has achieved LOD95 of 0.3 parts per million.